Robins Global News & Noticias 
Send2Press NewsWire Distribution Service
Newswire: OutcomeRx, a unit of CareMetx, announces First Independent Reinsurance Product for Rare Disease Specialty, Cell and Gene Therapies
- Details
- Category: Send2Press NewsWire Distribution Service
-
19 Nov 2020
- Last Updated: 19 November 2020
- Published: 19 November 2020
- Written by Send2Press NewsWire
Posted: 2020-11-19 07:30:14
Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.
Related News Stories From The Web And More
Related Bing News Search Results
Newswire: OutcomeRx, a unit of CareMetx, announces First Independent Reinsurance Product for Rare Disease Specialty, Cell and Gene Therapies | Send2Press NewsWire Distribution Service | RobinsPost News Network - Newscast
Insights into Neurogenesis and Aging: Potential Therapy for Degenerative Disease?
Tue, 24 Nov 2020 16:00:00 GMTStem cell-based therapies for brain repair The goal of stem ... An alternative strategy to grafting exogenous stem cells is to recruit rare, endogenous stem cells in non-neurogenic areas.
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million
Mon, 23 Nov 2020 05:15:00 GMTPRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it ...
OutcomeRx, a unit of CareMetx, announces First Independent Reinsurance Product for Rare Disease Specialty, Cell and Gene Therapies
Thu, 19 Nov 2020 11:50:00 GMTGene therapies are among the newest pharmaceutical innovations to treat and potentially cure disease ... rare diseases that have high cost therapies, such as CAR-Ts and traditional specialty ...
Insights into Neurogenesis and Aging: Potential Therapy for Degenerative Disease?
Sat, 14 Nov 2020 16:00:00 GMTThere will be a pressing need for new therapies ... disease as we approach the estimated threshold in the year 2050 when 20% of the population will be older than 65 years of age. The combination ...
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in ...
Thu, 12 Nov 2020 22:02:00 GMT(GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has granted PRIME ...
Related News Story Videos From Youtube
Blow Us A Whistle
Comments (Whistles) Designed By Disqus
